Chiblak Sara, Tang Zili, Lemke Dieter, Knoll Maximilian, Dokic Ivana, Warta Rolf, Moustafa Mahmoud, Mier Walter, Brons Stephan, Rapp Carmen, Muschal Stefan, Seidel Philipp, Bendszus Martin, Adeberg Sebastian, Wiestler Otmar D, Haberkorn Uwe, Debus Jürgen, Herold-Mende Christel, Wick Wolfgang, Abdollahi Amir
German Cancer Consortium, Heidelberg, Germany.
Division of Molecular & Translational Radiation Oncology, Heidelberg Ion Therapy Center (HIT), Heidelberg Institute of Radiation Oncology, Heidelberg University Medical School and National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.
JCI Insight. 2019 Jan 24;4(2):e123837. doi: 10.1172/jci.insight.123837.
Tumor radioresistance leading to local therapy failure remains a major obstacle for successful treatment of high-grade glioma. We hypothesized that distinct radiobiological features of particle therapy with carbon ions may circumvent glioma radioresistance. We demonstrate that carbon irradiation (CIR) efficiently eradicates radioresistant patient-derived glioma stem cells (GSCs), leading to growth inhibition and prolonged survival. The impact of CIR at the tumor-stroma interface was further investigated in 2 syngeneic mouse and 2 orthotopic GSC xenograft models. Intriguingly, tumor regressions and long-term local controls were observed at doses greater than or equal to 15-Gy CIR. Fractionated CIR further prolonged survival. The enhanced relative biological effectiveness of CIR in vivo was attributed to its potent antiangiogenic effects and eradication of radioresistant hypoxic tumor cells. Blockade of the HIF1-α/stromal cell-derived factor 1/CXCR4 axis by CIR reduced the recruitment of microglia and myeloid-derived suppressor cells (CD11b+Gr1+). Consequently, CIR abrogated M2-like immune polarization and enhanced the influx of CD8+ cells, generating an immunopermissive niche. We report that radiotherapy with carbon ions could surmount several central glioma resistance mechanisms by eradicating hypoxic and stem cell-like tumor cells, as well as modulating the glioma niche toward an antiangiogenic and less immunosuppressive state. Conclusively, potentially novel rationales for CIR in conquering glioma radioresistance are provided.
肿瘤放射抗性导致局部治疗失败仍然是高级别胶质瘤成功治疗的主要障碍。我们假设碳离子粒子治疗独特的放射生物学特性可能规避胶质瘤的放射抗性。我们证明碳离子照射(CIR)能有效根除源自患者的放射抗性胶质瘤干细胞(GSCs),导致生长抑制并延长生存期。在2个同基因小鼠模型和2个原位GSC异种移植模型中进一步研究了CIR在肿瘤-基质界面的作用。有趣的是,在剂量大于或等于15 Gy的CIR时观察到肿瘤消退和长期局部控制。分次CIR进一步延长了生存期。CIR在体内增强的相对生物学效应归因于其强大的抗血管生成作用和对放射抗性缺氧肿瘤细胞的根除。CIR对HIF1-α/基质细胞衍生因子1/CXCR4轴的阻断减少了小胶质细胞和髓源性抑制细胞(CD11b+Gr1+)的募集。因此,CIR消除了M2样免疫极化并增强了CD8+细胞的流入,产生了一个免疫允许的微环境。我们报告称,碳离子放射治疗可以通过根除缺氧和干细胞样肿瘤细胞,以及将胶质瘤微环境调节为抗血管生成和免疫抑制性较低的状态,来克服几种主要的胶质瘤抗性机制。总之,本文提供了CIR克服胶质瘤放射抗性的潜在新原理。